Regenerative Medicine

Evotec acquires cell therapy manufacturer

Tuesday 31 May 2022
Country
Germany

Evotec SE has expanded its capabilities in the field of cell therapy with the acquisition of the Italian company Rigenerand Srl, a 2009 spin-off of the University of Modena and Reggio Emilia. The acquisition, valued at €23 million, comes within weeks of Evotec’s agreement with Sernova Corp of Canada to develop a beta cell replacement therapy for diabetes. The prospective therapy will use induced pluripotent stem (iPS) cells produced by Evotec, combined with a pouch developed by Sernova.

Gene therapy for retinal disease

Saturday 23 April 2022
Country
Germany

A new gene therapy project has been launched by ViGeneron GmbH of Germany and Regeneron Pharmaceuticals Inc that would potentially result in the development of a treatment for an inherited retinal disorder. The two companies announced their collaboration on 6 April but did not identify the disease.

Gene therapy for myeloma

Tuesday 29 March 2022
Country
Netherlands

A cell-based gene therapy for multiple myeloma has been recommended by the European Medicines Agency for patients with multiple myeloma, an incurable blood cancer that causes plasma cells to grow out of control. Symptoms can include bone fracture or even kidney failure. The drug, Carvykti (ciltacabtagene autoleucel), is a chimeric antigen receptor (CAR) T cell medicine consisting of a patient’s own immune cells which have been engineered to target and kill cancer cells.

Novartis explores capsids

Tuesday 15 March 2022
Country
Switzerland

Novartis is to explore new ways of delivering gene therapies to the brain under a licence option agreement with Voyager Therapeutics Inc, a US company with adeno-associated virus (AAV) capsid technology. Under the agreement, the Swiss multinational may elect to license novel capsids for use in directing therapies against three undisclosed central nervous system (CNS) targets. Further out, it may exercise options for two additional targets. The goal is to develop gene therapies for neurological diseases that manifest in deep regions of the brain.

Cell therapy for rare disease

Monday 14 March 2022
Country
United States

An allogeneic cell therapy has been successfully used to treat patients 10 years and older with Duchenne muscular dystrophy, a rare genetic disease that affects both skeletal and cardiac muscle. The therapy, CAP-1002, was tested in a Phase 2, placebo-controlled trial and effectively reduced the deterioration of upper limb function in the patients as well as improved cardiac function. The results of the study, called HOPE-2, were published in The Lancet on 12 March 2022.

BioNTech strengthens position in engineered cell therapies

Tuesday 22 February 2022
Country
Germany

BioNTech SE has entered a three-year collaboration with Medigene AG to develop immunotherapies against solid tumours using Medigene’s proprietary T cell receptor (TCR) technology. This technology involves engineering a patient’s own T cells in order to display receptors that can recognise specific cancer antigens. Under the agreement, Medigene’s TCR discovery platform will be used in the development of cancer therapies against tumour targets nominated by BioNTech.

Oxford Biomedica gets manufacturing presence in US

Saturday 19 February 2022
Country
United Kingdom

UK-based Oxford Biomedica Plc is to establish a gene therapy manufacturing presence in the US under a new agreement with Homology Medicines Inc, a clinical-stage genetics medicines company located near Boston, US. Homology has experience in the development and use of adeno-associated virus (AAV) vectors while Oxford Biomedica has a lentiviral vector delivery platform.

Intellia acquires Rewrite Therapeutics

Saturday 19 February 2022
Country
United States

Intellia Therapeutics Inc has taken steps to advance its genome editing technology with the acquisition of Rewrite Therapeutics Inc. Intellia will pay Rewrite shareholders $45 million upfront and an additional $155 million and research and regulatory milestones through a mix of Intellia stock and cash. Further financial details were not disclosed.

Indapta Therapeutics raises $50 million in Series A financing

Saturday 19 February 2022
Country
United States

Indapta Therapeutics Inc of San Francisco, US, has raised $50 million in a Series A financing round to advance its technology for allogeneic natural killer (NK) cell therapies. This involves isolating and expanding a subset of NK cells known as G-NK cells, suitable for administration with a monoclonal antibody.

Hookipa and Gilead in HIV collaboration

Saturday 19 February 2022
Country
United States

Hookipa Pharma Inc is to take responsibility for advancing an antiviral drug candidate for HIV through early clinical development under an amended agreement with its partner Gilead Sciences Inc. Hookipa announced the recasting of the agreement on 15 February.